Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: David Jones who wrote (2122)	2/24/1999 2:11:00 PM
From: Joe	Respond to of 4140

David, if you look down to the section entitled REGULATORY MATTERS on page 9, you will find the reference. I don't think this is cause for alarm. I know it happened with BEAM and several of the other laser companies in refractive surgery. I don't think it happened with VISX, but then again, they did not get approval on their first pass because of discrepancies in their clinical data. Joe

To: David Jones who wrote (2122)	2/24/1999 5:44:00 PM
From: RockDoc	Read Replies (1) \| Respond to of 4140

The filing definitely mentioned it. But SNRS didn't specify exactly what "representations" were made in which particular press release(s) that prompted the letter from from the FDA. As far as I'm concerned , it's not a big deal. I'm sure this stuff happens all the time in dealing with the red tape bureaucratic bs with the FDA. Next big news will be the announcement of the Ophthalmic Devices Panel meeting. My guess is July instead of May. Their recommendation for approval will be rubberstamped by the FDA and we'll be off to the races. I expect a double in price from here on the day the Panel issues its recommendation. Just my opinion. The ROCKSTER